Ciprofloxacin Hydrochloride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317535

CAS#: 93107-08-5 (HCl)

Description: Ciprofloxacin hydrochloride is a broad-spectrum antimicrobial carboxyfluoroquinoline, an fluoroquinolone antibiotic that is widely used as an antimicrobial and immunomodulatory agent. It is capable of inducing respiratory, urinary tract, gastrointestinal, and abdominal infections. It functions by inhibiting DNA gyrase (a type II topoisomerase) and topoisomerase IV, the enzymes responsible for negative supercoiling of chromosomes and DNA strand separation, thus blocking initiation of bacterial replication. Most recently ciprofloxacin has been used in the management of postexposure inhalational anthrax and radiation combined injury resulting from nuclear disasters.

Chemical Structure

img
Ciprofloxacin Hydrochloride
CAS# 93107-08-5 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 317535
Name: Ciprofloxacin Hydrochloride
CAS#: 93107-08-5 (HCl)
Chemical Formula: C17H19ClFN3O3
Exact Mass: 0.00
Molecular Weight: 367.800
Elemental Analysis: C, 55.51; H, 5.21; Cl, 9.64; F, 5.17; N, 11.42; O, 13.05

Price and Availability

Size Price Availability Quantity
5g USD 350 2 Weeks
10g USD 550 2 Weeks
25g USD 850 2 Weeks
Bulk inquiry

Related CAS #: 85721-33-1 (free base)   86393-32-0 (HCl hydrate)   86483-48-9 (HCl)   96186-80-0 (lactate)   93107-08-5 (HCl)    

Synonym: Ciprofloxacin hydrochloride; Ciloxan; Ceprimax; Oftacilox; Ciprofloxacin hydrochloride monohydrate; Proquin XR; Hydrochloride Anhydrous, Ciprofloxacin; Hydrochloride, Ciprofloxacin; Monohydrate, Ciprofloxacin Monohydrochloride; Monohydrochloride Monohydrate, Ciprofloxacin;

IUPAC/Chemical Name: cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, monohydrochloride

InChi Key: DIOIOSKKIYDRIQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H18FN3O3.ClH/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24;/h7-10,19H,1-6H2,(H,23,24);1H

SMILES Code: FC1=CC2=C(C=C1N3CCNCC3)N(C4CC4)C=C(C(O)=O)C2=O.Cl

Appearance: White to light yellow crystalline powder.

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 367.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: El-Kosasy AM, Abdel-Aziz O, Magdy N, El Zahar NM. Spectrophotometric and
chemometric methods for determination of imipenem, ciprofloxacin hydrochloride,
dexamethasone sodium phosphate, paracetamol and cilastatin sodium in human urine.
Spectrochim Acta A Mol Biomol Spectrosc. 2015 Dec 12;157:26-33. doi:
10.1016/j.saa.2015.12.011. [Epub ahead of print] PubMed PMID: 26709018.


2: Abdelkader H, Mansour HF. Comparative studies for ciprofloxacin hydrochloride
pre-formed gels and thermally triggered (in situ) gels: in vitro and in vivo
appraisal using a bacterial keratitis model in rabbits. Pharm Dev Technol. 2015
Jun;20(4):410-6. doi: 10.3109/10837450.2013.871034. Epub 2014 Jan 6. PubMed PMID:
24392945.


3: Zhu SN, Guo ZB, Zhao YF, Ge X, Wei Y, Chen S, Wang J. [Radiolytic
Decomposition of Ciprofloxacin Hydrochloride in Aqueous Solution Using γ
Irradiation]. Huan Jing Ke Xue. 2015 Apr;36(4):1332-7. Chinese. PubMed PMID:
26164908.


4: Mobarak DH, Salah S, Elkheshen SA. Formulation of ciprofloxacin hydrochloride
loaded biodegradable nanoparticles: optimization of technique and process
variables. Pharm Dev Technol. 2014 Nov;19(7):891-900. doi:
10.3109/10837450.2013.836293. Epub 2013 Sep 13. PubMed PMID: 24032531.


5: Stojkovic A, Parojcic J, Djuric Z, Corrigan OI. A case study of in silico
modelling of ciprofloxacin hydrochloride/metallic compound interactions. AAPS
PharmSciTech. 2014 Apr;15(2):270-8. doi: 10.1208/s12249-013-0055-x. Epub 2013 Dec
5. PubMed PMID: 24306676; PubMed Central PMCID: PMC3969494.


6: Gaikwad VD, Yadav VD, Gaikwad MD. Novel sustained release and swellable
gastroretentive dosage form for ciprofloxacin hydrochloride. Int J Pharm
Investig. 2014 Apr;4(2):88-92. doi: 10.4103/2230-973X.133057. PubMed PMID:
25006553; PubMed Central PMCID: PMC4083538.


7: Singh KP, Chhabra G, Sharma V, Pathak K. Thermosensitive periodontal sol of
ciprofloxacin hydrochloride and serratiopeptidase: Pharmaceutical and mechanical
analysis. Int J Pharm Investig. 2014 Jan;4(1):5-14. doi:
10.4103/2230-973X.127734. PubMed PMID: 24678456; PubMed Central PMCID:
PMC3944617.


8: Yoshikawa T, Takahashi Y, Kawaguchi H, Utsunomiya S, Miura N, Izumi H, Miyoshi
N, Tanimoto A. A dermal phototoxicity study following intravenous infusion
administration of ciprofloxacin hydrochloride in the novel microminipigs. Toxicol
Pathol. 2013 Jan;41(1):109-13. doi: 10.1177/0192623312452489. Epub 2012 Jul 5.
PubMed PMID: 22767873.


9: Fahmy R, Kona R, Dandu R, Xie W, Claycamp G, Hoag SW. Quality by design I:
Application of failure mode effect analysis (FMEA) and Plackett-Burman design of
experiments in the identification of "main factors" in the formulation and
process design space for roller-compacted ciprofloxacin hydrochloride
immediate-release tablets. AAPS PharmSciTech. 2012 Dec;13(4):1243-54. doi:
10.1208/s12249-012-9844-x. Epub 2012 Sep 20. PubMed PMID: 22993122; PubMed
Central PMCID: PMC3513475.


10: Başaran B, Bozkir A. Thermosensitive and pH induced in situ ophthalmic
gelling system for ciprofloxacin hydrochloride: hydroxypropyl-beta-cyclodextrin
complex. Acta Pol Pharm. 2012 Nov-Dec;69(6):1137-47. PubMed PMID: 23285675.


11: Shah M, Agrawal YK, Garala K, Ramkishan A. Solid lipid nanoparticles of a
water soluble drug, ciprofloxacin hydrochloride. Indian J Pharm Sci. 2012
Sep;74(5):434-42. doi: 10.4103/0250-474X.108419. PubMed PMID: 23716872; PubMed
Central PMCID: PMC3660870.


12: Verma A, Bansal AK, Ghosh A, Pandit JK. Low molecular mass chitosan as
carrier for a hydrodynamically balanced system for sustained delivery of
ciprofloxacin hydrochloride. Acta Pharm. 2012 Jun;62(2):237-50. doi:
10.2478/v10007-012-0013-2. PubMed PMID: 22750821.


13: Sakamoto T, Portieri A, Arnone DD, Taday PF, Kawanishi T, Hiyama Y. Coating
and Density Distribution Analysis of Commercial Ciprofloxacin Hydrochloride
Monohydrate Tablets by Terahertz Pulsed Spectroscopy and Imaging. J Pharm Innov.
2012 Jun;7(2):87-93. Epub 2012 May 25. PubMed PMID: 22707994; PubMed Central
PMCID: PMC3366064.


14: Anand U, Kurup L, Mukherjee S. Deciphering the role of pH in the binding of
ciprofloxacin hydrochloride to bovine serum albumin. Phys Chem Chem Phys. 2012
Mar 28;14(12):4250-8. doi: 10.1039/c2cp00001f. Epub 2012 Feb 21. PubMed PMID:
22354288.


15: Shah M, Agrawal Y. Ciprofloxacin hydrochloride-loaded glyceryl monostearate
nanoparticle: factorial design of Lutrol F68 and Phospholipon 90G. J
Microencapsul. 2012;29(4):331-43. doi: 10.3109/02652048.2011.651498. Epub 2012
Jan 18. PubMed PMID: 22251240.


16: Mostafavi A, Emami J, Varshosaz J, Davies NM, Rezazadeh M. Development of a
prolonged-release gastroretentive tablet formulation of ciprofloxacin
hydrochloride: pharmacokinetic characterization in healthy human volunteers. Int
J Pharm. 2011 May 16;409(1-2):128-36. doi: 10.1016/j.ijpharm.2011.02.035. Epub
2011 Mar 1. PubMed PMID: 21371548.


17: Mahrouse MA, Elkady EF. Validated spectrophotometric methods for the
simultaneous determination of ciprofloxacin hydrochloride and metronidazole in
tablets. Chem Pharm Bull (Tokyo). 2011;59(12):1485-93. PubMed PMID: 22130371.


18: Abdelbary G. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated
liposomes. Pharm Dev Technol. 2011 Feb;16(1):44-56. doi:
10.3109/10837450903479988. Epub 2009 Dec 21. PubMed PMID: 20025433.


19: Olivera ME, Manzo RH, Junginger HE, Midha KK, Shah VP, Stavchansky S,
Dressman JB, Barends DM. Biowaiver monographs for immediate release solid oral
dosage forms: ciprofloxacin hydrochloride. J Pharm Sci. 2011 Jan;100(1):22-33.
doi: 10.1002/jps.22259. Review. PubMed PMID: 20602455.


20: Tadros MI. Controlled-release effervescent floating matrix tablets of
ciprofloxacin hydrochloride: development, optimization and in vitro-in vivo
evaluation in healthy human volunteers. Eur J Pharm Biopharm. 2010
Feb;74(2):332-9. doi: 10.1016/j.ejpb.2009.11.010. Epub 2009 Nov 22. PubMed PMID:
19932750.